Abstract
Comment on Hill et al, page [2559][1] Previous optimism about the complement inhibitor eculizumab as a treatment for hemolytic paroxysmal nocturnal hemoglobinuria (PNH) is sustained with a report in this issue of Blood by Hill and colleagues. In 1938, Jordan,[1][2] Dacie et al,[2][3] and Ham[3][4
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
